

# CENTER FOR DRUG EVALUATION AND RESEARCH

## Approval Package for:

### ***APPLICATION NUMBER:***

**215910Orig1s000**

***Trade Name:*** Sezaby for injection

***Generic or Proper Name:*** Phenobarbital sodium

***Sponsor:*** Sun Pharma Advanced Research Company, Ltd.

***Approval Date:*** November 17<sup>th</sup>, 2022

***Indication:*** Treatment of neonatal seizures in term and preterm infants.

# CENTER FOR DRUG EVALUATION AND RESEARCH

215910Orig1s000

## CONTENTS

|                                                           |
|-----------------------------------------------------------|
| <b>Reviews / Information Included in this NDA Review.</b> |
|-----------------------------------------------------------|

|                                                      |          |
|------------------------------------------------------|----------|
| <b>Approval Letter</b>                               | <b>X</b> |
| <b>Other Action Letters</b>                          |          |
| <b>Labeling</b>                                      | <b>X</b> |
| <b>REMS</b>                                          |          |
| <b>Summary Review</b>                                | <b>X</b> |
| <b>Officer/Employee List</b>                         | <b>X</b> |
| <b>Office Director Memo</b>                          |          |
| <b>Cross Discipline Team Leader Review</b>           |          |
| <b>Clinical Review(s)</b>                            | <b>X</b> |
| <b>Product Quality Review(s)</b>                     | <b>X</b> |
| <b>Non-Clinical Review(s)</b>                        | <b>X</b> |
| <b>Statistical Review(s)</b>                         | <b>X</b> |
| <b>Clinical Microbiology / Virology Review(s)</b>    |          |
| <b>Clinical Pharmacology Review(s)</b>               | <b>X</b> |
| <b>Other Reviews</b>                                 | <b>X</b> |
| <b>Risk Assessment and Risk Mitigation Review(s)</b> |          |
| <b>Proprietary Name Review(s)</b>                    | <b>X</b> |
| <b>Administrative/Correspondence Document(s)</b>     |          |

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

***APPLICATION NUMBER:***

**215910Orig1s000**

**APPROVAL LETTER**



NDA 215910

**NDA APPROVAL**

Sun Pharma Advanced Research Company, Ltd.  
c/o Sun Pharmaceutical Industries, Inc.  
Attention: Esin Kosal, PhD  
Vice President, Global Regulatory Affairs  
1 Commerce Drive  
Cranbury, NJ 08512

Dear Dr. Kosal:

Please refer to your new drug application (NDA) dated and received February 17, 2022, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Sezaby (phenobarbital sodium) for injection.

We acknowledge receipt of your major amendment dated June 3, 2022, which extended the goal date by three months.

This NDA provides for the use of Sezaby (phenobarbital sodium) for injection for the treatment of neonatal seizures in term and preterm infants.

**APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.<sup>1</sup> Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information) as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>

The SPL will be accessible via publicly available labeling repositories.

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

**CARTON AND CONTAINER LABELING**

Submit final printed carton and container labeling that are identical to the carton and container labeling submitted on November 15, 2022, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *SPL Standard for Content of Labeling Technical Qs & As*. For administrative purposes, designate this submission “**Final Printed Carton and Container Labeling for approved NDA 215910.**” Approval of this submission by FDA is not required before the labeling is used.

**DATING PERIOD**

Based on the stability data submitted to date, the expiry dating period for Sezaby (phenobarbital sodium) for injection shall be 24 months from the date of manufacture when stored at 20°C to 25°C.

**RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER**

Your request for a rare pediatric disease priority review voucher is denied. This application is not eligible for a rare pediatric disease priority review voucher because, at the time of approval, it is not an application for a drug “that contains no active moiety (as defined by the Secretary in section 314.3 of title 21, Code of Federal Regulations (or any successor regulations)) that has been previously approved in any other application under subsection (b)(1), (b)(2), or (j) of section 505” of the FD&C Act. Section 529(a)(4)(B)(i)(I) of the FD&C Act. Please refer to our separate General Correspondence letter dated November 17, 2022, for further explanation.

**REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because this drug product for this indication has an orphan drug designation, you are exempt from this requirement.

**POSTMARKETING REQUIREMENTS UNDER 505(o)**

Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act (FDCA) authorizes FDA to require holders of approved drug and biological product applications to conduct postmarketing studies and clinical trials for certain purposes, if FDA makes certain findings required by the statute.

We have determined that an analysis of spontaneous postmarketing adverse events reported under subsection 505(k)(1) of the FDCA will not be sufficient to assess a signal of a serious risk of long-term neurodevelopmental effects of Sezaby in patients with neonatal seizures.

Furthermore, the active postmarket risk identification and analysis system as available under section 505(k)(3) of the FDCA will not be sufficient to assess this serious risk. Therefore, based on appropriate scientific data, FDA has determined that you are required to conduct the following study:

- 4353-1 Conduct a prospective study with appropriate comparator(s) to assess long-term neurodevelopmental effects of Sezaby in patients with neonatal seizures. Ensure capture of and adjustment for potential confounders. Assess neurodevelopmental effects using validated, age-appropriate developmental assessments of motor skills, cognition, language, and behavior. Follow patients for a minimum of 5 years.

The timetable you submitted on November 7, 2022, states that you will conduct this study according to the following schedule:

|                            |         |
|----------------------------|---------|
| Draft Protocol Submission: | 06/2023 |
| Final Protocol Submission: | 02/2024 |
| Study Completion:          | 02/2034 |
| Final Report Submission:   | 02/2035 |

FDA considers the term *final* to mean that the applicant has submitted a protocol, the FDA review team has sent comments to the applicant, and the protocol has been revised as needed to meet the goal of the study or clinical trial.<sup>3</sup>

Finally, we have determined that only a clinical trial (rather than a nonclinical or observational study) will be sufficient to assess a signal of a serious risk of prolongation of the QT interval.

Therefore, based on appropriate scientific data, FDA has determined that you are required to conduct the following trial:

- 4353-2 An evaluation of the effects of Sezaby on the QTc interval designed according to ICH E14 guidance for industry E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs (October 2015) and E14 Clinical Evaluation of

---

<sup>3</sup> See the guidance for Industry *Postmarketing Studies and Clinical Trials—Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act* (October 2019).

<https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

**U.S. Food and Drug Administration**  
Silver Spring, MD 20993  
[www.fda.gov](https://www.fda.gov)

QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs — Questions and Answers (February 2022).

The timetable you submitted on November 1, 2022, states that you will conduct this trial according to the following schedule:

|                            |         |
|----------------------------|---------|
| Draft Protocol Submission: | 06/2023 |
| Final Protocol Submission: | 12/2023 |
| Study Completion:          | 12/2025 |
| Final Report Submission:   | 12/2026 |

Submit clinical protocol(s) to your IND 132342, with a cross-reference letter to this NDA. Submit nonclinical and chemistry, manufacturing, and controls protocols and all final report(s) to your NDA. Prominently identify the submission with the following wording in bold capital letters at the top of the first page of the submission, as appropriate:

**Required Postmarketing Protocol Under 505(o), Required Postmarketing Final Report Under 505(o), Required Postmarketing Correspondence Under 505(o).**

Submission of the protocol(s) for required postmarketing observational studies to your IND is for purposes of administrative tracking only. These studies do not constitute clinical investigations pursuant to 21 CFR 312.3(b) and therefore are not subject to the IND requirements under 21 CFR part 312.

Section 505(o)(3)(E)(ii) of the FDCA requires you to report periodically on the status of any study or clinical trial required under this section. This section also requires you to periodically report to FDA on the status of any study or clinical trial otherwise undertaken to investigate a safety issue. Section 506B of the FDCA, as well as 21 CFR 314.81(b)(2)(vii), requires you to report annually on the status of any postmarketing commitments or required studies or clinical trials.

FDA will consider the submission of your annual report under section 506B and 21 CFR 314.81(b)(2)(vii) to satisfy the periodic reporting requirement under section 505(o)(3)(E)(ii) provided that you include the elements listed in 505(o) and 21 CFR 314.81(b)(2)(vii). We remind you that to comply with 505(o), your annual report must also include a report on the status of any study or clinical trial otherwise undertaken to investigate a safety issue. Failure to submit an annual report for studies or clinical trials required under 505(o) on the date required will be considered a violation of FDCA section 505(o)(3)(E)(ii) and could result in enforcement action.

### **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-*

*Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs.*<sup>4</sup>

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.<sup>5</sup> Information and Instructions for completing the form can be found at FDA.gov.<sup>6</sup>

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Josephine Little, Regulatory Project Manager, via email at Josephine.Little@fda.hhs.gov.

Sincerely,

*{See appended electronic signature page}*

Nick Kozauer, MD  
Director  
Division of Neurology 2  
Office of Neuroscience  
Center for Drug Evaluation and Research

**ENCLOSURE(S):**

- Content of Labeling
  - Prescribing Information

---

<sup>4</sup> For the most recent version of a guidance, check the FDA guidance web page at

<https://www.fda.gov/media/128163/download>.

<sup>5</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

<sup>6</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>



-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

NICHOLAS A KOZAUER  
11/17/2022 10:33:57 AM